Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13204Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Mahesh, R. | - |
| dc.date.accessioned | 2023-11-21T06:41:36Z | - |
| dc.date.available | 2023-11-21T06:41:36Z | - |
| dc.date.issued | 2015 | - |
| dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399007/ | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13204 | - |
| dc.description.abstract | In the last few decades, serotonin type-3 (5-HT3) receptor antagonists have been identified as potential targets for anxiety disorders. In preclinical studies, 5-HT3 antagonists have shown promising antianxiety effects. In this study, a novel 5-HT3 receptor antagonist, QCM-13(N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) was evaluated for anxiolytic-like activity in rodent behavioral test battery. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | PMC | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | PMC | en_US |
| dc.subject | Anti-anxiety agent | en_US |
| dc.title | Pharmacological evaluation of novel 5-HT3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.